Search research articles
Contact Us
Filters
Showing results (61-70 of 147) with videos related to
Page
of 15
Sort By:
Cancer Research
|
November 16, 2011
Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition
Klaus P Hoeflich, Mark Merchant, Christine Orr, et al.
Nature Cancer
|
May 7, 2026
A high-MAPK, low-WNT cell state drives metastatic dissemination in colorectal cancer
Melanie Heinlein, Ginny X Li, Noelyn Kljavin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 21, 2005
Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer
Adrian M Jubb, Herbert I Hurwitz, Wei Bai, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 13, 2011
Impact of exploratory biomarkers on the treatment effect of bevacizumab in metastatic breast cancer
Adrian M Jubb, Kathy D Miller, Hope S Rugo, et al.
JCO Precision Oncology
|
February 9, 2022
Effects of Molecular Heterogeneity on Survival of Patients With <i>BRAF</i><sup>V600</sup>-Mutated Melanoma Treated With Vemurafenib With or Without Cobimetinib in the coBRIM Study
Matthew J Wongchenko, Antoni Ribas, Paolo A Ascierto, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
October 29, 2017
Molecular and Histopathological Characterization of the Tumor Immune Microenvironment in Advanced Stage of Malignant Pleural Mesothelioma
Namrata S Patil, Luisella Righi, Hartmut Koeppen, et al.
Clinical Lung Cancer
|
July 6, 2021
Comparison of SP142 and 22C3 Immunohistochemistry PD-L1 Assays for Clinical Efficacy of Atezolizumab in Non-Small Cell Lung Cancer: Results From the Randomized OAK Trial
Shirish Gadgeel, Fred R Hirsch, Keith Kerr, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 8, 2013
Loss of NAPRT1 expression by tumor-specific promoter methylation provides a novel predictive biomarker for NAMPT inhibitors
David S Shames, Kristi Elkins, Kimberly Walter, et al.
The Journal of Pathology
|
May 21, 2011
Notch3 signalling promotes tumour growth in colorectal cancer
Valentina Serafin, Luca Persano, Lidia Moserle, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
April 13, 2011
Targeting p21-activated kinase 1 (PAK1) to induce apoptosis of tumor cells
Christy C Ong, Adrian M Jubb, Peter M Haverty, et al.
Page
of 15
Search research articles
Search
Showing results (61-70 of 147) with videos related to
Sort By:
Page
of 15
Cancer Research
|
November 16, 2011
Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition
Klaus P Hoeflich, Mark Merchant, Christine Orr, et al.
Nature Cancer
|
May 7, 2026
A high-MAPK, low-WNT cell state drives metastatic dissemination in colorectal cancer
Melanie Heinlein, Ginny X Li, Noelyn Kljavin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 21, 2005
Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer
Adrian M Jubb, Herbert I Hurwitz, Wei Bai, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 13, 2011
Impact of exploratory biomarkers on the treatment effect of bevacizumab in metastatic breast cancer
Adrian M Jubb, Kathy D Miller, Hope S Rugo, et al.
JCO Precision Oncology
|
February 9, 2022
Effects of Molecular Heterogeneity on Survival of Patients With <i>BRAF</i><sup>V600</sup>-Mutated Melanoma Treated With Vemurafenib With or Without Cobimetinib in the coBRIM Study
Matthew J Wongchenko, Antoni Ribas, Paolo A Ascierto, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
October 29, 2017
Molecular and Histopathological Characterization of the Tumor Immune Microenvironment in Advanced Stage of Malignant Pleural Mesothelioma
Namrata S Patil, Luisella Righi, Hartmut Koeppen, et al.
Clinical Lung Cancer
|
July 6, 2021
Comparison of SP142 and 22C3 Immunohistochemistry PD-L1 Assays for Clinical Efficacy of Atezolizumab in Non-Small Cell Lung Cancer: Results From the Randomized OAK Trial
Shirish Gadgeel, Fred R Hirsch, Keith Kerr, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 8, 2013
Loss of NAPRT1 expression by tumor-specific promoter methylation provides a novel predictive biomarker for NAMPT inhibitors
David S Shames, Kristi Elkins, Kimberly Walter, et al.
The Journal of Pathology
|
May 21, 2011
Notch3 signalling promotes tumour growth in colorectal cancer
Valentina Serafin, Luca Persano, Lidia Moserle, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
April 13, 2011
Targeting p21-activated kinase 1 (PAK1) to induce apoptosis of tumor cells
Christy C Ong, Adrian M Jubb, Peter M Haverty, et al.
Page
of 15